Clicky

Day One Biopharmaceuticals, Inc.(DAWN)

Description: Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.


Keywords: Cancer Biopharmaceutical Enzymes Protein Kinase Inhibitor Signal Transduction Kinase Protein Kinase Fibrosarcoma Ym Biosciences

Home Page: dayonebio.com

DAWN Technical Analysis

395 Oyster Point Boulevard
South San Francisco, CA 94080
United States
Phone: 650 484 0899


Officers

Name Title
Dr. Jeremy Bender M.B.A., Ph.D. CEO, Pres & Director
Dr. Samuel C. Blackman M.D., Ph.D. Co-Founder & Chief Medical Officer
Ms. Julie Papanek Grant M.B.A. Co-Founder & Director
Mr. Charles N. York II COO, CFO & Sec.
Dr. Mike Preigh Ph.D. Chief of Technology Operations
Mr. Adam Dubow Gen. Counsel
Ms. Jaa Roberson Chief People Officer
Dr. Davy Chiodin Ph.D., Pharm.D. Chief Devel. Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 3.98
Price-to-Book MRQ: 4.1528
Price-to-Sales TTM: 0
IPO Date: 2021-05-27
Fiscal Year End: December
Full Time Employees: 102
Back to stocks